In a groundbreaking development, Actym Therapeutics has secured US patents for their innovative STACT™ biological platform. This platform offers a versatile approach to delivering large, multiplexed plasmid payloads to specific cells, microenvironments, and tissues via systemic administration. By leveraging this technology, Actym can facilitate the expression of various therapeutic agents, such as RNA, proteins, peptides, and gene editing tools, in targeted human cells or bacterial vehicles. Moreover, the platform’s engineered auxotrophy feature enables precise localization and enrichment in tissues, making it applicable to both oncology and non-oncology treatments. Actym’s flagship product, ACTM-838, harnesses the STACT™ platform to deliver IL-15plex and eSTING payloads directly to tumor microenvironments, triggering a localized immune response against tumors while minimizing systemic toxicity. This milestone underscores Actym Therapeutics’ commitment to advancing RNA therapeutics and revolutionizing targeted drug delivery in the field of oncology.
Read more about this — here
